0 282

Cited 8 times in

Blood Pressure Classification Using the 2017 ACC/AHA Guideline and Heart Failure in Patients With Cancer

Authors
 Hidehiro Kaneko  ;  Yuichiro Yano  ;  Hokyou Lee  ;  Hyeok-Hee Lee  ;  Akira Okada  ;  Yuta Suzuki  ;  Hidetaka Itoh  ;  Satoshi Matsuoka  ;  Katsuhito Fujiu  ;  Nobuaki Michihata  ;  Taisuke Jo  ;  Norifumi Takeda  ;  Hiroyuki Morita  ;  Akira Nishiyama  ;  Koichi Node  ;  Hyeon Chang Kim  ;  Hideo Yasunaga  ;  Issei Komuro 
Citation
 JOURNAL OF CLINICAL ONCOLOGY, Vol.41(5) : 980-990, 2023-02 
Journal Title
JOURNAL OF CLINICAL ONCOLOGY
ISSN
 0732-183X 
Issue Date
2023-02
MeSH
Blood Pressure ; Cardiology* ; Cardiovascular Diseases* / complications ; Female ; Heart Failure* ; Humans ; Hypertension* ; Male ; Middle Aged ; Neoplasms* / complications ; Risk Factors ; United States
Abstract
Purpose: Despite the growing recognition of the importance of hypertension in patients with cancer, little is known about whether high blood pressure (BP) among patients with cancer is associated with incident heart failure (HF) and other cardiovascular disease (CVD) events and what BP levels are linked to these events. We examined the association of BP classification on the basis of the 2017 American College of Cardiology/American Heart Association BP guideline with the risk of HF and CVD events in patients with cancer.

Methods: We studied 33,991 patients with a history of breast, colorectal, or stomach cancer (median age, 53 years; 34.1% men). Patients receiving treatment with BP-lowering medications or having a history of CVD including HF were excluded. Using BP measurements at baseline, 33,991 participants were categorized as having normal BP (n = 17,444), elevated BP (n = 4,733), stage 1 hypertension (n = 7,502), or stage 2 hypertension (n = 4,312). The primary outcome was HF.

Results: Over a mean follow-up of 2.6 ± 2.2 years, 779 HF events were recorded. After multivariable adjustment, the hazard ratios (HRs) for HF were 1.15 (95% CI, 0.93 to 1.44) for elevated BP, 1.24 (95% CI, 1.03 to 1.49) for stage 1 hypertension, and 1.99 (95% CI, 1.63 to 2.43) for stage 2 hypertension. A stepwise increase in risk with BP categories was also observed in other CVD events. This association was observed even in patients undergoing active cancer treatment. The relationship between hypertension and the risk of developing HF in patients with cancer was confirmed in the Korean National Health Insurance Service database.

Conclusion: Medication-naïve stage 1 and 2 hypertension was associated with a greater risk of HF and other CVD events in patients with cancer. Our results suggest the importance of multidisciplinary collaboration (eg, oncologists and cardiologists) to establish the optimal management strategy for hypertension in patients with cancer.
Full Text
https://ascopubs.org/doi/10.1200/JCO.22.00083
DOI
10.1200/JCO.22.00083
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Preventive Medicine (예방의학교실) > 1. Journal Papers
Yonsei Authors
Kim, Hyeon Chang(김현창) ORCID logo https://orcid.org/0000-0001-7867-1240
Lee, Hokyou(이호규) ORCID logo https://orcid.org/0000-0002-5034-8422
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/193683
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links